Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
this study is aimed to evaluate the efficacy and safety of the combination of Niraparib and
Sintilimab in the treatment of recurrent/metastatic nasopharyngeal carcinoma